Compare Edwards Lifesciences Corporation Common Stock (EW) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edwards Lifesciences Corporation Common Stock vs Marqeta Inc — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $84.25 (market cap $49.44B), while Marqeta Inc trades at $17.36 (market cap $1.78B). The key difference: Edwards Lifesciences Corporation Common Stock is far larger — about 27.8× Marqeta Inc's market cap, and Edwards Lifesciences Corporation Common Stock is more actively traded (3,508,027 versus 1,087,097). Which is the better fit depends on your goals.
| EW | MQ | |
|---|---|---|
Market Cap | $49.44B | $1.78B |
Volume | 3,508,027 | 1,087,097 |
Sector | Health | Technology |
52-Week High | $95.18 | $20.32 |
52-Week Low | $72.65 | $15.04 |
Enterprise Value | $45.90B | $1.09B |
Typical Hold Time | — | 44 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Marqeta (MQ) trades at $17.44, up 5.38% with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with three consecutive quarterly EPS beats and positive cash flow trends, though valuation remains elevated with a P/E of 189.56. Recent partnerships with BVNK for stablecoin cards and Google for kids' wallets highlight strategic growth initiatives.
While technical indicators suggest near-term strength, the stock faces fundamental challenges with negative net income and high valuation multiples. Analyst consensus is cautious with a $11.38 price target below current levels, indicating 31.82% buy ratings. Key risks include contract renewals in Q3 2026 and growth moderation expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
